Clinical Trials Directory

We are doing this study to compare two different treatment options for mantle cell lymphoma. We want to find out which option has the best outcomes for older adults. We will compare the results of continuous treatment with zanubritinib to treatment with zanubrutinib that is stopped after the initial six 28-day cycles of chemotherapy and restarted only if your disease gets worse following the initial six 28-day cycles of chemotherapy.

We are doing this study to see if combining immunotherapy with chemotherapy is a better treatment than chemotherapy alone for NSCLC.

We are doing this study to help create a national biobank of samples and data about patients who experience side effects when they take immunotherapy drugs for their cancer. We want to find out why some people experience side effects and why others do not. We also want to learn more about how to diagnose and treat these side effects more effectively.

We are doing this study to test a new strategy to help people quit smoking. We want to know if the study approach is better than the usual approach. The usual approach is to encourage patients to quit smoking using cessation support manuals and either medication or nicotine replacement products. We want to know if the study approach works better for cancer survivors who live in rural areas.

We are doing this study to find out if an experimental drug called ABBV-400 (the study drug) is a safe and effective option for treating colorectal cancer when it is combined with the following standard-of-care drugs: 5-fluorouracil, folinic acid, and bevacizumab. We are also trying to find the best dose and frequency of ABBV-400 to use.

We are doing this study to collect information about people with oligometastasis for future use.

We are doing this study to find out if certain experimental drug combinations are safe and effective options for people who have recurrent or persistent endometrial cancer (cancer that has come back after treatment or does not respond to treatment).

We are doing this study to find out if carefully watching patients with low risk germ cell tumors after surgery will have different results than treating people with chemotherapy afer their surgery. For people who are in standard risk groups related to germ cell tumors, we want to compare the effects of carboplatin with cisplatin and find out which of these drugs seems to work better.